Cheynew good morning,
We all know this is a thin stock with an ATM program so the price of the day could end up anywhere. However, why not suspend the cynicism for just five minutes and really look at the results.
The overall MOS seems to be improved by about 45% against similar tests. Granted this is not a double blind randomized test but this is very interesting data. This is a big step forward percentage wise.
A better question is why, when you look at the pipeline data on the PPHM site you cant even find a phase II breast cancer entry?? The only entry I find is phase I IST. Makes you wonder what else is missing from the web site and why???
Follow up question is where PPHM goes from here with breast cancer and what this means to the overall bidding corporately. In light of the Avastin failure does this study carry real weight for partnering??
Regards,
RRdog
News 
Market Data 
Discover 
AI
